Aurobindo Pharma

Aurobindo Pharma gains on acquisition deal with Activis

Aurobindo Pharma gains on acquisition deal with ActivisIn response to Aurobindo Pharma acquisition deal with Dublin-based Actavis Plc, shares of the Indian pharmaceuticals firm jumped more than 4 per cent to hit a high of Rs 402 apiece on Monday.

Aurobindo announced that it would acquire Actavis' commercial operations in seven western European countries, viz.  Belgium, Italy, France, Spain, Portugal, Germany and the Netherlands.

The transaction will cost Aurobindo _30 million.  The Indian company has plans to fund the acquisition through internal accruals.

Aurobindo to acquire Actavis Plc’s commercial operations in 7 European markets

Aurobindo to acquire Actavis Plc’s commercial operations in 7 European marketsDrug maker Aurobindo Pharma on Saturday confirmed its decision to acquire commercial operations of Dublin-based Actavis Plc in seven western European countries.

The acquisition will cost Aurobindo 30 million euros, and the pharmaceuticals giant has plans to fund the deal through internal accruals.

US FDA removes import alert on Aurobindo Hydrabad plant

US FDA removes import alert on Aurobindo Hydrabad plantThe United States Food and Drug Administration (FDA) has removed an import alert on the products produced at the Hyderabad unit of Aurobindo Pharma.

The company cited FDA's website post to state that the Americna regulator has removed the import alert on non-sterile products manufactured at Unit, VI cephalosporin facility. Aurobindo Pharma manufactures Cephalosporins antibiotics, which are used to treat infections caused by bacteria at the unit in Hyderabad.

Indian Market Continues With Uptrend; Gold Finance Companies Gain

Indian Market Continues With Uptrend; Gold Finance Companies GainIndian Stock Markets continued in the positive territory on Thursday as the US markets gained smartly on Wednesday. Stock prices of Gold Loan companies witnessed huge demand after reports of loan valuation for gold ratio increase to 75 per cent.

JSW Steel has increased price of all steel products of the company. The stock price was higher in today's session. Maruti Suzuki and M&M witnessed higher sales during December compared to other auto majors facing tough times.

Aurobindo Pharma approves USFDA approval for Ondansetron injections

Aurobindo Pharma approves USFDA approval for Ondansetron injectionsPrivate sector firm, Aurobindo Pharma has received an approval from the US Food & Drug Administration (USFDA) for manufacturing and marketing Ondansetron injections from the company's Unit IV formulation facility in Hyderabad.

The Ondansetron Injections are a generic version of GlaxoSmithKline's Zofran injection. These injections are recommended for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy or postoperative nausea and/or vomiting.

Aurobindo Pharma’s profit falls 14 per cent

Aurobindo Pharma’s profit falls 14 per centPrivate sector firm, Aurobindo Pharma has reported a fall of 13.6 per cent fall in net profit to Rs 108 crore during the fourth quarter of the financial year till March 2012.

The company had reported net profit of Rs 125 crore during the same quarter of the previous year, according to a company statement. The company’s total income grew at 2.5 per cent to Rs 1,170 crore during the quarter from Rs 1,142 crore in the previous fiscal.

Aurobindo Bags USFDA Nod For Lamivudine & Zidovudine Tabs

Aurobindo Bags USFDA Nod For Lamivudine & Zidovudine TabsAurobindo Pharma Limited has pocketed final authorization from the US Food and Drug Administration (FDA) to produce and sell lamivudine and zidovudine tabs USP 150/300mg (ANDA 202418).

Hyderabad-based pharma major said that it is ready to launch the Lamivudine and zidovudine pills in the market.

Lamivudine and zidovudine tabs, the generic equivalent of ViiV Healthcare firm's Combivir tabs, are prescribed as part of antiretroviral (ARV) combination therapy for the cure of HIV infected people.

Aurobindo Pharma Long Term Buy Call

Aurobindo Pharma Long Term Buy CallTechnical analyst PN Vijay has maintained 'buy' rating on Aurobindo Pharma Limited stock to attain a target of Rs 300.

According to analyst, the said target can be achieved within a period of 12 to 18 months.

The stock of the bank, on April 27, closed at Rs 195.20 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 19.31 and 10.19 respectively.

The share price has seen a 52-week high of Rs 275 and a low of Rs 157.25 on BSE.

Aurobindo Pharma Short Term Buy Call

Aurobindo Pharma Short Term Buy CallTechnical analyst Gaurang Shah of Geojit BNP Paribas has maintained 'buy' rating on Aurobindo Pharma Limited stock for 15-20% returns.

According to analyst, the interested investors can buy the stock on dips to around Rs 165.

Today, the stock of the company opened at Rs 171.90 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 275 and a low of Rs 157.25 on BSE.

Current EPS & P/E ratio stood at 19.31 and 9.02 respectively.

Angel Broking recommends `Buy’ on Aurobindo Pharmaceuticals

Aurobindo-PharmaAngel Broking recommends `Buy’ on Aurobindo Pharmaceuticals. The broking firm has predicted that the stock may reach a price target of Rs 210 soon. It has mentioned in the recent report of the broking firm dated Feb. 25, 2011. Aurobindo Pharma (APL) has announced that it has received an import alert for the detention of products from its Cephalosporin facility (Unit VI).

The USFDA has imposed this import alert on Aurobindo Pharma (APL). Its Cephalosporin facility is located in Andhra Pradesh, India.

Buy Aurobindo Pharma With Stop Loss Of Rs 1154

Buy Aurobindo Pharma With Stop Loss Of Rs 1154Technical analyst Anil Singhvi has maintained 'buy' rating on Aurobindo Pharma Limited stock with an intraday target of Rs 1240.

According to analyst, the investors can purchase the stock with a stop loss of Rs 1154.

The stock of the bank, on February 04, closed at Rs 1175 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1375 and a low of Rs 786.25 on BSE.

Current EPS & P/E ratio stood at 96.56 and 12.25 respectively.

Aurobindo Pharma Bags Tentative US FDA Nod For Levofloxacin Tabs

Remote controlled bomb caused blast in PhilippinesAurobindo Pharma Limited has bagged tentative nod from the US Food & Drug Administration to make and sell Levofloxacin tablets in the American market.

The company bagged nod to manufacture and market the drug, the generic equivalent of Ortho McNeil Janssen Pharmaceutical Inc's Levaquin pills, in the potencies of 250mg, 500mg and 750mg.

Levofloxacin pills 250mg, 500mg, and 750mg are suggested to cure bacterial illnesses including chronic bronchitis, bacterial sinusitis, pneumonia, skin and skin structure diseases in grownups.

Buy Aurobindo Pharma Ltd: Fairwealth Securities

Aurobindo-Pharma-5.jpgAurobindo Pharma Ltd (APL) started as a pure API supplier has now scaled its business to focus more on formulations. The company has a strong presence in the antibiotic space especially in the segments of penicillin and cephalosporins and the anti-retroviral segment. After establishing a presence in the semi regulated markets, the company began to venture into the regulated markets of US and Europe and these are expected to become key growth drivers going forward. Till date, it has commercialized over 200 API's and 300 formulation products with 15 manufacturing facilities across the globe approved by USFDA and other regulators.

Buy Aurobindo Pharma With Stop Loss Of Rs 1326

Buy Aurobindo Pharma With Stop Loss Of Rs 1326Technical analyst Hemen Kapadia has maintained 'buy' rating on Bharti Airtel Limited stock with an intra-day target of Rs 1350.

According to analyst, the stock can be purchased at Rs 1334 with a stop loss of Rs 1326.

The stock of the company, on December 21, closed at Rs 1334.20 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1349 and a low of Rs 786.85 on BSE.

Current EPS & P/E ratio stood 81.76 and 16.18 respectively.

Buy Aurobindo Pharma With Target Of Rs 1350

Buy Aurobindo Pharma With Target Of Rs 1350Technical analyst Ashish Chaturmotha of Anand Rathi Securities has maintained 'buy' rating on Aurobindo Pharma Limited with a short term target of Rs 1350.

The analyst said that the stock can be purchased with a stop loss of Rs 1250.

Today, the stock of the company opened at Rs 1280 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1349 and a low of Rs 786.25 on BSE.

Current EPS & P/E ratio stood at 81.76 and 15.44 respectively.

Short Term Buy Call For Aurobindo Pharma

Short Term Buy Call For Aurobindo PharmaTechnical analyst Kunal Sarogi has maintained 'buy' rating on Aurobindo Pharma Ltd stock with a stop loss of Rs 1200.

According to analyst, the investors can buy the stock with a target of Rs 1370.

Today, the stock of the company opened at Rs 1249.95 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1349 and a low of Rs 786.25 on BSE.

Current EPS & P/E ratio stood at 81.76 and 15.22 respectively.

Buy Aurobindo Pharma With Stop Loss Of Rs 1,069.90

Buy Aurobindo Pharma With Stop Loss Of Rs 1,069.90Stock market analyst Rajesh Gupta of Fairwealth Securities has maintained 'buy' rating on Aurobindo Pharma Limited stock with a target of 1,130.

According to analyst, the interested investors can buy the stock above Rs 1085 with a strict stop loss of Rs 1069.90.

The stock of the company, on Sep 20, closed at Rs 1094.45 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 1109.85 and a low of Rs 680 on BSE.

Current EPS & P/E ratio stood at 79.40 and 13.78 respectively.

Aurobindo first quarter net dips 69% to Rs 51 crore

Aurobindo-PharmaLeading drug maker of the country, Aurobindo Pharma has informed that there has been a huge decline in its net profit figure. It has declared its first quarter financial results for the financial year 2010-11.

The company has posted a net profit of Rs 51.50 crore for the June quarter of the year which is almost 69.08% decline from the net profit registered by the same company a year ago in the similar fiscal year. However, there has been a hike in the net sales of the company in this Q1.

Aurobindo Receives Tentative Nod For Resuvastatin Calclum Tabs From USFDA

Aurobindo Receives Tentative Nod For Resuvastatin Calclum Tabs From USFDAAurobindo Pharma has declared that the US FDA has given tentative nod for Rosuvastatin Calclum pills in strengths of 5mg, 10mg, 20mg and 40mg.

According to the company, Resuvastatin Calclum tabs, which comes under cardio vascular (CVS) therapeutic family, treats high LDL cholesterol and total cholesterol level.

For the year ended Dec 31, 2009, Resuvastatin Calclum tabs hold a market size of $ 2.9 billion in the United States.

Aurobindo Pharma Limited Buy Call: StocksIdea.com

Aurobindo

Company was founded in 1986 by Mr. P. V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly commited professionals; Aurobindo Pharma became a public company in 1992. Aurobindo Pharma Limited based at Hyderabad, India manufactures generic pharmaceuticals and Active Pharmaceutical Ingredients. Company is one of the world's top 5 manufacturers of semi synthetic penicillin’s. Company has Asia's largest sterile API facility. It is one of India’s top 5 pharma companies ranked in terms of turnover.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content